Would you continue durvalumab beyond 12 months in an oligometastatic NSCLC patient treated with concurrent CRT followed by consolidation durvalumab after treating a single metastatic site?  

There are really a few questions here. The first is duration of durvalumab, and I agree with prior answer by @Karen L. Reckamp that stopping at 1 year is appropriate given that was specified in PACIFIC (though only 42% of patients actually completed 1 yr of durvalumab in the study). Then there ...